Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.60 |
| ▸ | CCR2 | P41597 | 5/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CCR4 | P51679 | 2/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | CCR9 | P51686 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762431 | 0.92 | CYP2C9 (0.57) | CYP3A4CCR2CYP2C9TNNI3KBRAF | |
| SCHEMBL12594251 | 0.91 | CYP3A4 (0.63) | CYP3A4CCR2CYP2C9TNNI3KBRAF | |
| SCHEMBL1762385 | 0.87 | CYP3A4 (0.79) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL26066327 | 0.86 | CYP3A4 (0.56) | CYP3A4CCR2CYP2C9TNNI3KNUDT1 | |
| SCHEMBL1762314 | 0.83 | CYP2C9 (0.58) | CYP3A4CCR2CYP2C9TNNI3KBRAF | |
| SCHEMBL1762514 | 0.82 | CYP2C9 (0.61) | CYP3A4CCR2CYP2C9CYP2C19CCR4 | |
| SCHEMBL1762423 | 0.82 | CYP2C9 (0.56) | CYP3A4CCR2CYP2C9NUDT1CYP2C19 | |
| SCHEMBL22461745 | 0.81 | CYP3A4 (0.67) | CYP3A4CCR2CYP2C9TNNI3KNUDT1 | |
| SCHEMBL12648498 | 0.81 | CYP2C9 (0.57) | CYP3A4CCR2CYP2C9TNNI3KBRAF | |
| SCHEMBL12594373 | 0.81 | CYP2C9 (0.55) | CYP3A4CCR2CYP2C9TNNI3KNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| US-20200297708-A1 | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-24 | — | — | US | disclosed |
| WO-2020191240-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR | CHEMOCENTRYX, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190269664-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | CYP3A4 3623/4885CCR2 1/4885CYP2C9 3132/4885 |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CYP3A4 3935/4885CCR2 1/4885CYP2C9 3501/4885 |
| US-20200297708-A1 | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor | PDCD1LG2, CCR2, CD274 | CYP3A4 4440/4885CCR2 2/4885CYP2C9 4045/4885 |
| US-20190269664-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | CYP3A4 3623/4885CCR2 1/4885CYP2C9 3132/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CYP3A4 3935/4885CCR2 1/4885CYP2C9 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.